Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levobetaxolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betaxolol SCHEMBL23530 | 1.00 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL4997902 | 1.00 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL23531 | 1.00 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL6512495 | 1.00 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL42794 | 0.99 | LMNA (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL26664826 | 0.99 | ADRB1 (0.98) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Levobetaxolol SCHEMBL42795 | 0.99 | LMNA (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL26664823 | 0.99 | ADRB1 (0.98) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Levobetaxolol SCHEMBL1649403 | 0.98 | ADRB1 (0.96) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL613385 | 0.98 | ADRB1 (0.96) | ADRB1LMNACYP2D6MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26154 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6335335-B1 | — | — | None | — | — | US | claimed |
| WO-2026102187-A1 | ENGINEERED VIRUS-LIKE PARTICLES COMPRISING A BASE EDITOR FOR THE TREATMENT OF GLAUCOMA, AND APPLICATIONS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260090984-A1 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | MEDIPRINT OPHTHALMICS INC. (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| WO-1987007141-A1 | METHOD FOR TREATING GLAUCOMA | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1987-12-03 | — | — | WO | claimed |
| EP-0227818-A1 | ANTIGLAUCOMA COMPOSITIONS. | SCHERING CORP (US) | 1987-07-08 | — | — | EP | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| WO-1987000055-A1 | ANTIGLAUCOMA COMPOSITIONS | SCHERING CORPORATION (US) | 1987-01-15 | — | — | WO | claimed |
| EP-0194178-A1 | Pharmaceutical compositions of betaxolol and nifedipine | SYNTHELABO (FR) | 1986-09-10 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |